Clik here to view.
Otsuka to buy Avanir Pharma for $3.5-billion
Japanese drug maker Otsuka Holdings plans to buy Avanir Pharmaceuticals for about $3.5-billion to expand its neurologic drug portfolio ahead of an expiration of a key drug patent in April 2015....
View ArticleClik here to view.
Transition Therapeutics prices $20-million stock offering
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has priced a public offering of 3,076,923 common shares at $6.50 each for gross proceeds of $20-million. The company also has granted underwriters a...
View ArticleClik here to view.
Transition completes enrollment with ELND005 in AD
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has completed enrolment of the Phase 2 clinical study evaluating its neuropsychiatric drug candidate, ELND005, as a treatment for agitation and aggression...
View ArticleClik here to view.
Transition posts positive AME, renal clearance studies with ELND005
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported positive results from two Phase 1 clinical studies of its neuropsychiatric drug candidate ELND005. The studies were an absorption metabolism...
View ArticleClik here to view.
Transition licenses Phase 2 drug candidate from Lilly
Transition Therapeutics (NASDAQ:TTHI: TSX:TTH), through its wholly-owned subsidiary, Transition Therapeutics Ireland Ltd. (TTIL), has exclusively licensed worldwide rights to a novel small molecule...
View ArticleClik here to view.
Transition Therapeutics appoints Damiani as president
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has appointed Carl Damiani as president and COO. Carl Damiani Since joining Transition in 2003, Mr. Damiani has held roles of COO, VP of business...
View ArticleClik here to view.
Transition Therapeutics to pursue Phase 3 program in AD
Dr. Tony Cruz Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has completed a thorough review of the data from a Phase 2/3 study of ELND005 in Alzheimer’s disease (AD) patients with moderate or severe...
View ArticleClik here to view.
Transition Therapeutics sets Phase 2 SARM trial
Dr. Tony Cruz Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has entered an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital (BWH)....
View ArticleClik here to view.
Transition Therapeutics reports TT401 trial results
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes. TT401 is a once-weekly administered...
View ArticleClik here to view.
Transition Therapeutics begins Phase 2 SARM study
Transition Therapeutics (NASDAQ:TTHI, TSX:TTH) has dosed the first patient in a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate, TT701. The Phase 2 study will evaluate the...
View Article
